Comparative Pharmacology
Head-to-head clinical analysis: EPI E Z PEN JR versus PSEUDOEPHEDRINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPI E Z PEN JR versus PSEUDOEPHEDRINE HYDROCHLORIDE.
EPI E Z PEN JR vs PSEUDOEPHEDRINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Epinephrine is a direct-acting sympathomimetic amine that acts on alpha- and beta-adrenergic receptors. Alpha receptor activation increases peripheral vascular resistance and reverses hypotension, while beta receptor activation causes bronchodilation, increased heart rate, and myocardial contractility.
Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion. It also has weak beta-adrenergic activity.
Epinephrine 0.3 mg (0.3 mL of 1:1000 solution) intramuscularly into the anterolateral thigh, repeated every 5-15 minutes as necessary for anaphylaxis.
60 mg orally every 4 to 6 hours as needed; maximum 240 mg per day.
None Documented
None Documented
Short terminal half-life of approximately 2-3 minutes; requires continuous infusion for sustained effect due to rapid uptake and metabolism.
Terminal elimination half-life: 5-8 hours in adults with normal renal function, prolonged in renal impairment (up to 16-20 hours in severe impairment)
Primarily renal: epinephrine is metabolized in the liver and tissues, with metabolites (metanephrine, vanillylmandelic acid) excreted in urine; <5% excreted unchanged.
Renal: 70-90% unchanged via glomerular filtration and tubular secretion; fecal: <1%; biliary: minimal
Category C
Category A/B
Sympathomimetic
Sympathomimetic